All Stories

  1. Design and Synthesis of New Pyrazolo[1,5‐ c ]quinazolin‐5‐amines as Potential TLR7/8 Modulators
  2. SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody
  3. Advax delta inulin adjuvant accelerates humoral anti-influenza response
  4. Delta inulin alone or combined with CpG oligonucleotide enhances antibody‐dependent influenza vaccine protection in mice and nonhuman primate newborns
  5. One Health adjuvant selection for vaccines against zoonotic infections
  6. Magnetoencephalography Reveals Neuroprotective Effects of COVID-19 Vaccination in Non-Human Primates
  7. Virus-like particle-based vaccines targeting theAnophelesmosquito salivary protein, TRIO
  8. Post-Hoc Analysis of Potential Correlates of Protection of a Recombinant SARS-CoV-2 Spike Protein Extracellular Domain Vaccine Formulated with Advax-CpG55.2-Adjuvant
  9. MultiTEP-Based Vaccines Targeting SARS-CoV-2 Spike Protein IgG Epitopes Elicit Robust Binding Antibody Titers with Limited Virus-Neutralizing Activity
  10. Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine
  11. Dendritic cell–specific intercellular adhesion molecule‐3‐grabbing nonintegrin (DC‐SIGN) is a cellular receptor for delta inulin adjuvant
  12. Structure–Activity Relationships toward the Identification of a High-Potency Selective Human Toll-like Receptor-7 Agonist
  13. Structure-activity relationship in NOD2 agonistic muramyl dipeptides
  14. Advax-SM™-Adjuvanted COBRA (H1/H3) Hemagglutinin Influenza Vaccines
  15. Immunogenicity and Protective Efficacy of Psoralen-Inactivated SARS-CoV-2 Vaccine in Nonhuman Primates
  16. Structure−Activity Relationships Towards the Identification of High-Potency Selective Human Toll-Like Receptor-7 Agonist
  17. Safety and immunogenicity of an adjuvanted recombinant spike protein‐based severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccine, SpikeVet™, in selected Carnivora, Primates and Artiodactyla in Australian zoos
  18. Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates
  19. Lung IL-17A-Producing CD4+ T Cells Correlate with Protection after Intrapulmonary Vaccination with Differentially Adjuvanted Tuberculosis Vaccines
  20. Comparative immunogenicity and safety of SpikoGen®, a recombinant SARS-CoV-2 spike protein vaccine in children and young adults: An immuno-bridging clinical trial
  21. A Multiseason Randomized Controlled Trial of Advax-Adjuvanted Seasonal Influenza Vaccine in Participants With Chronic Disease or Older Age
  22. Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants
  23. Structure-Activity Relationship in NOD2 Agonistic Muramyl Dipeptides
  24. An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection
  25. Developmental and reproductive safety of Advax-CpG55.2™ adjuvanted COVID-19 and influenza vaccines in mice
  26. An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice
  27. Author Correction: An intranasal vaccine comprising SARS‑CoV‑2 spike receptor‑binding domain protein entrapped in mannose‑conjugated chitosan nanoparticle provides protection in hamsters
  28. Evaluation of a SARS-CoV-2 spike protein ectodomain subunit vaccine with a squalene emulsion adjuvant in rodents and rhesus macaques
  29. An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in hamsters
  30. Adjuvanted Fusion Protein Vaccine Induces Durable Immunity to Onchocerca volvulus in Mice and Non-Human Primates
  31. An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge
  32. Detection, characterization, and persistence of Campylobacter hepaticus, the cause of spotty liver disease in layer hens
  33. Ability of SpikoGen®, an Advax‐CpG adjuvanted recombinant spike protein vaccine, to induce cross‐neutralising antibodies against SARS‐CoV‐2 variants
  34. Lignin nanoparticles as a novel carrier for efficacious delivery of toll like receptor 7/8 agonist: Physicochemical and in-vitro evaluation
  35. Identifying SARS-CoV-2 Drugs Binding to the Spike Fatty Acid Binding Pocket Using In Silico Docking and Molecular Dynamics
  36. An alternative protein-based vaccine against COVID-19
  37. A recombinant Artemisia vulgaris pollen adjuvanted Art v 1 protein-based vaccine treats allergic rhinitis and bronchial asthma using pre- and co-seasonal ultrashort immunotherapy regimens in sensitized mice
  38. Mucosal immunization with a delta-inulin adjuvanted recombinant spike vaccine elicits lung-resident immune memory and protects mice against SARS-CoV-2
  39. Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates
  40. Prior respiratory syncytial virus infection reduces vaccine-mediated Th2-skewed immunity, but retains enhanced RSV F-specific CD8 T cell responses elicited by a Th1-skewing vaccine formulation
  41. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics
  42. Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom
  43. Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations
  44. Narrative Review: Obesity, Type 2 DM and Obstructive Sleep Apnoea—Common Bedfellows
  45. Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS‐CoV‐2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo‐controlled trial
  46. Potential COVID-19 Therapies from Computational Repurposing of Drugs and Natural Products against the SARS-CoV-2 Helicase
  47. A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates
  48. Co-Administration of Adjuvanted Recombinant Ov-103 and Ov-RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine Onchocerca ochengi Infection Model of Human Onchocerciasis
  49. Enhanced Immunogenicity of Inactivated Dengue Vaccines by Novel Polysaccharide-Based Adjuvants in Mice
  50. Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters
  51. Identification of adjuvants for γδ T cells in response to a novel M. tuberculosis vaccine antigen
  52. Correction: Stewart et al. Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity. Microorganisms 2019, 7, 255
  53. Evaluation of a Novel Adjuvanted Vaccine for Ultrashort Regimen Therapy of Artemisia Pollen-Induced Allergic Bronchial Asthma in a Mouse Model
  54. Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (Mpro) as Potential COVID-19 Therapies
  55. A Spike Protein-Based Subunit SARS-CoV-2 Vaccine for Pets: Safety, Immunogenicity, and Protective Efficacy in Juvenile Cats
  56. A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model
  57. Potential COVID-19 therapies from computational repurposing of drugs and natural products against the SARS-CoV-2 helicase
  58. An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission
  59. Combined delivery of TLR2 and TLR7 agonists by Nanostructured lipid carriers induces potent vaccine adjuvant activity in mice
  60. Stereoisomeric Pam2CS based TLR2 agonists: synthesis, structural modelling and activity as vaccine adjuvants
  61. Artificial Intelligence in Vaccine and Drug Design
  62. Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates
  63. A Spike protein-based subunit SARS-CoV-2 vaccine for pets: safety, immunogenicity, and protective efficacy in juvenile cats
  64. A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model
  65. An Advax-Adjuvanted Inactivated Cell-Culture Derived Japanese Encephalitis Vaccine Induces Broadly Neutralising Anti-Flavivirus Antibodies, Robust Cellular Immunity and Provides Single Dose Protection
  66. Rapid Development of Analytical Methods for Evaluating Pandemic Vaccines: A Covid-19 Perspective
  67. An Advax-adjuvanted Inactivated Cell-culture Japanese Encephalitis Vaccine Induces Broadly Neutralising Anti-flavivirus Antibodies and T-cell Immunity and Provides Single Dose Protection
  68. Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom
  69. An appeal for an objective, open, and transparent scientific debate about the origin of SARS-CoV-2
  70. An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission
  71. Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies
  72. Author Correction: In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin
  73. Toll-like receptor-7/8 agonist kill Leishmania amazonensis by acting as pro-oxidant and pro-inflammatory agent
  74. A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection
  75. Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection
  76. Combination Adjuvants Enhance Recombinant Protein Vaccine Protection against Fungal Infection
  77. A M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization
  78. Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection
  79. Impaired Ca2+ signaling due to hepatic steatosis mediates hepatic insulin resistance in Alström syndrome mice that is reversed by GLP-1 analog treatment
  80. In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin
  81. Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice
  82. Intrapulmonary vaccination with delta-inulin adjuvant stimulates non-polarised chemotactic signalling and diverse cellular interaction
  83. Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines
  84. Intranasal powder live attenuated influenza vaccine is thermostable, immunogenic, and protective against homologous challenge in ferrets
  85. Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity
  86. Combination adjuvants enhance recombinant protein vaccine protection against fungal infection
  87. Accelerated vaccine induction of IgM neutralising antibody enables vaccine protection against same day lethal influenza virus challenge
  88. Onchocerca volvulus bivalent subunit vaccine induces protective immunity in genetically diverse collaborative cross recombinant inbred intercross mice
  89. An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein
  90. Strategies for active and passive pediatric RSV immunization
  91. Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles
  92. TLR2 Agonistic Small Molecules: Detailed Structure–Activity Relationship, Applications, and Future Prospects
  93. Developing Translational Vaccines against Heroin and Fentanyl through Investigation of Adjuvants and Stability
  94. Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis
  95. Maternal immunization with adjuvanted RSV prefusion F protein effectively protects offspring from RSV challenge and alters innate and T cell immunity
  96. Advax adjuvant formulations promote protective immunity against aerosolMycobacterium tuberculosisin the absence of deleterious inflammation and reactogenicity
  97. Relative Adipose Tissue Failure in Alström Syndrome Drives Obesity-Induced Insulin Resistance
  98. Flavivirus DNA Vaccine Design and Adjuvant Selection
  99. An Epitope-based Malaria Vaccine Targeting the Junctional Domain of Circumsporozoite Protein
  100. Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection
  101. Adjuvant selection impacts the correlates of vaccine protection against Ebola infection
  102. Influence of Oxidation Degree on the Physicochemical Properties of Oxidized Inulin
  103. Vaccine-Induced Th1-Type Response Protects against Invasive Group A Streptococcus Infection in the Absence of Opsonizing Antibodies
  104. BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant
  105. Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependant protection against pulmonary tuberculosis
  106. Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology
  107. Prediction of novel mouse TLR9 agonists using a random forest approach
  108. Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice
  109. Doxorubicin-Loaded Delta Inulin Conjugates for Controlled and Targeted Drug Delivery: Development, Characterization, and In Vitro Evaluation
  110. A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice
  111. Synthesis and Characterization of pH-Sensitive Inulin Conjugate of Isoniazid for Monocyte-Targeted Delivery
  112. Review of polysaccharide particle-based functional drug delivery
  113. MicroRNA-Related Genetic Variants Are Associated With Diabetic Retinopathy in Type 1 Diabetes Mellitus
  114. Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity
  115. Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy
  116. Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy
  117. Use of adjuvants to make neonatal vaccines more effective
  118. Design and Characterization of Inulin Conjugate for Improved Intracellular and Targeted Delivery of Pyrazinoic Acid to Monocytes
  119. Calcium Signaling As a Therapeutic Target for Liver Steatosis
  120. A Microfluidic Tumor‐on‐a‐Chip for Assessing Multifunctional Liposomes' Tumor Targeting and Anticancer Efficacy
  121. Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas
  122. Microfluidic formation of core-shell alginate microparticles for protein encapsulation and controlled release
  123. Mitochondrial haplogroups are not associated with diabetic retinopathy in a large Australian and British Caucasian sample
  124. Synthesis and characterization of a novel inulin hydrogel crosslinked with pyromellitic dianhydride
  125. Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge
  126. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
  127. The Safety of an Adjuvanted Autologous Cancer Vaccine Platform in Canine Cancer Patients
  128. Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge
  129. Genome-wide association studies for diabetic macular edema and proliferative diabetic retinopathy
  130. Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats
  131. Proteomic analysis of influenza haemagglutinin-specific antibodies following vaccination reveals convergent immunoglobulin variable region signatures
  132. Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of four protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection
  133. Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against Mycobacterium tuberculosis infection
  134. DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant
  135. Investigation of the biodistribution, breakdown and excretion of delta inulin adjuvant
  136. X-ray crystal structure of rivoglitazone bound to PPARγ and PPAR subtype selectivity of TZDs
  137. Multistage vaccines containing outer membrane, type III secretion system and inclusion membrane proteins protects against a Chlamydia genital tract infection and pathology
  138. Panblok-H1+advax H1N1/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine
  139. Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines
  140. Molecular Adjuvants for DNA Vaccines
  141. Vaccine Adjuvant Nanotechnologies
  142. ALMS1 acts as a critical molecular switch that controls Insulin-stimulated glucose transport in adipocytes
  143. Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens
  144. Influenza immunization during pregnancy: Benefits for mother and infant
  145. The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice
  146. Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant
  147. Alzheimer’s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules
  148. Physical characterization and in silico modeling of inulin polymer conformation during vaccine adjuvant particle formation
  149. Vaxine
  150. Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology
  151. A single-nucleotide polymorphism in the MicroRNA-146a gene is associated with diabetic nephropathy and sight-threatening diabetic retinopathy in Caucasian patients
  152. Genetic predisposition for beta cell fragility underlies type 1 and type 2 diabetes
  153. Promoter polymorphism at the tumour necrosis factor/lymphotoxin-alpha locus is associated with type of diabetes but not with susceptibility to sight-threatening diabetic retinopathy
  154. Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant
  155. SARS coronavirus infections of the lower respiratory tract and their prevention
  156. Molecular mechanisms for enhanced DNA vaccine immunogenicity
  157. Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety
  158. Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
  159. Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single–dose influenza vaccine protection
  160. Common Sequence Variation in the VEGFC Gene Is Associated with Diabetic Retinopathy and Diabetic Macular Edema
  161. Identification and characterisation of T-cell epitopes for incorporation into dendritic cell-delivered Listeria vaccines
  162. Novel nanoparticle vaccines for Listeriosis
  163. Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene
  164. A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease
  165. Delta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza Vaccine
  166. Inulin crystal initiation via a glucose-fructose cross-link of adjacent polymer chains: Atomic force microscopy and static molecular modelling
  167. A gold glyco-nanoparticle carrying a listeriolysin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against listeria infection
  168. Pulmonary immunisation
  169. Characterisation of adjuvants for use in dromedary immunisation
  170. Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology
  171. Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals
  172. Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: A randomized controlled Phase 1 study
  173. Editorial (Thematic Issue: The Coming of Age of DNA Vaccines)
  174. Plasmids Encoding Protein Aggregation Domains Act As Molecular Adjuvants for DNA Vaccines
  175. A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection
  176. In Silico Structural Homology Modelling and Docking for Assessment of Pandemic Potential of a Novel H7N9 Influenza Virus and Its Ability to Be Neutralized by Existing Anti-Hemagglutinin Antibodies
  177. Inulin isoforms differ by repeated additions of one crystal unit cell
  178. Advax-Adjuvanted Recombinant Protective Antigen Provides Protection against Inhalational Anthrax That Is Further Enhanced by Addition of Murabutide Adjuvant
  179. Gamma ray sterilization of delta inulin adjuvant particles (Advax™) makes minor, partly reversible structural changes without affecting adjuvant activity
  180. Sugar-Based Immune Adjuvants for Use in Recombinant, Viral Vector, DNA and Other Styles of Vaccines
  181. Genetic study of diabetic retinopathy: recruitment methodology and analysis of baseline characteristics
  182. Chiral Self-Assembly of Designed Amphiphiles: Influences on Aggregate Morphology
  183. An Inactivated Cell Culture Japanese Encephalitis Vaccine (JE-ADVAX) Formulated with Delta Inulin Adjuvant Provides Robust Heterologous Protection against West Nile Encephalitis via Cross-Protective Memory B Cells and Neutralizing Antibody
  184. Pulmonary Hypertension in Chronic Lung Diseases and/or Hypoxia
  185. The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions
  186. Vaccine adjuvants: in search of new paradigms
  187. Vaccine adjuvant safety: the elephant in the room
  188. A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing
  189. Flu watch
  190. Computational vaccinology and the ICoVax 2012 workshop
  191. JE-ADVAX Vaccine Protection against Japanese Encephalitis Virus Mediated by Memory B Cells in the Absence of CD8+ T Cells and Pre-Exposure Neutralizing Antibody
  192. Systems Immunology, Vaccine Adjuvant
  193. Unconventional Vaccines: Progress and Challenges
  194. A randomized controlled study to assess the immunogenicity and tolerability of a 2012 trivalent seasonal inactivated influenza vaccine administered via a disposable syringe jet injector device versus a traditional pre-filled syringe and needle
  195. Immunotherapy – 2076. A controlled study of delta inulin-adjuvanted honey bee venom immunotherapy
  196. The future of human DNA vaccines
  197. Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses
  198. BBS-Induced Ciliary Defect Enhances Adipogenesis, Causing Paradoxical Higher-Insulin Sensitivity, Glucose Usage, and Decreased Inflammatory Response
  199. Characterization in rabbits & nonhuman primates of the neutralizing antibody response elicited by DNA & protein vaccination with SIVmac251 & SIVsmE660
  200. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant
  201. Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses
  202. Report from the field
  203. Analysis of the hydrolysis of inulin using real time 1H NMR spectroscopy
  204. Relationship between DDAH gene variants and serum ADMA level in individuals with type 1 diabetes
  205. Technologies for enhanced efficacy of DNA vaccines
  206. Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment
  207. Observation of the keto tautomer of d-fructose in D2O using 1H NMR spectroscopy
  208. Dyspnea in Pulmonary Arterial Hypertension
  209. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets
  210. Effects of perindopril–indapamide on left ventricular diastolic function and mass in patients with type 2 diabetes: the ADVANCE Echocardiography Substudy
  211. Pediatric influenza immunization
  212. Serological responses following influenza A H1N1 2009 infection in adults
  213. Carbohydrate-based immune adjuvants
  214. The Vaccine Renaissance
  215. Challenges in improving influenza vaccine protection in the elderly
  216. World Vaccine Congress Asia 2011 (June 20-24, 2011, Singapore)
  217. Immunome Research-Five Years On
  218. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations
  219. Alström syndrome: insights into the pathogenesis of metabolic disorders
  220. Delta inulin: a novel, immunologically active, stable packing structure comprising  -D-[2 -> 1] poly(fructo-furanosyl)  -D-glucose polymers
  221. Lessons learned from the H1N1 2009 pandemic
  222. Management of dyspnea in advanced pulmonary arterial hypertension
  223. Aldose Reductase Gene Polymorphisms and Diabetic Retinopathy Susceptibility
  224. Immunomodulation with microbial vaccines to prevent type 1 diabetes mellitus
  225. Sequence Variation in DDAH1 and DDAH2 Genes Is Strongly and Additively Associated with Serum ADMA Concentrations in Individuals with Type 2 Diabetes
  226. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses
  227. Association Between Erythropoietin Gene Polymorphisms and Diabetic Retinopathy
  228. Common Sequence Variation in theVEGFAGene Predicts Risk of Diabetic Retinopathy
  229. Focus on Influenza vaccines
  230. P11-21. Induction of persistent mucosal humoral and cellular responses following immunization of mice with HIV-1 envelope protein in inulin-derived adjuvants
  231. Diabetic Retinopathy Is Associated With Elevated Serum Asymmetric and Symmetric Dimethylarginines
  232. The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line
  233. Pharmacological Management of Endocrine Conditions in the Elderly Patient
  234. AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5
  235. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
  236. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial
  237. Antisaccade deficits in subjects either genetically or clinically at risk for schizophrenia
  238. 4-Hydroxydocosahexaenoic acid, a potent peroxisome proliferator-activated receptor γ agonist alleviates the symptoms of DSS-induced colitis
  239. Freeing vaccine adjuvants from dangerous immunological dogma
  240. Data Extraction for Improved Prediction Outcomes in Organ Transplantation — A Hybrid Approach
  241. Fat Aussie—A New Alström Syndrome Mouse Showing a Critical Role for ALMS1 in Obesity, Diabetes, and Spermatogenesis
  242. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity
  243. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice
  244. Bioinformatics for study of autoimmunity
  245. PREDNOD, a prediction server for peptide binding to the H-2g7haplotype of the non-obese diabetic mouse
  246. Type 1 Diabetes: Immunology and Genetics
  247. The Transcriptional Landscape of the Mammalian Genome
  248. Temporal regulation of the human immune system
  249. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
  250. Assessment of cardiovascular disease risk factors and diabetes mellitus in Australian prisons: is the prisoner population unhealthier than the rest of the Australian population?
  251. Information technologies for vaccine research
  252. Immunoinformatics and its relevance to understanding human immune disease
  253. Hypothyroidism and hyponatraemia in the hospital setting
  254. Dexamethasone Infusion Testing in the Diagnosis of Cushing's Syndrome
  255. A Hybrid Decision Tree – Artificial Neural Networks Ensemble Approach for Kidney Transplantation Outcomes Prediction
  256. Virtual models of the HLA class I antigen processing pathway
  257. Identification of Key β Cell Gene Signaling Pathways Involved in Type 1 Diabetes
  258. The Power of an Integrated Informatic and Molecular Approach to Type 1 Diabetes Research
  259. Addison's disease presenting in four adolescents with type 1 diabetes
  260. Computational methods for prediction of T-cell epitopes—a framework for modelling, testing, and applications
  261. Inulin‐derived adjuvants efficiently promote both Th1 and Th2 immune responses
  262. Elevated Lymphocyte Expression of CLIP Is Associated with Type 1 Diabetes and May Be a Useful Marker of Autoimmune Susceptibility
  263. A rash: Part 1
  264. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]
  265. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen
  266. Vaccine adjuvants: Current state and future trends
  267. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial
  268. The perils of untimed serum cortisol measurement
  269. Identification of "pathologs" (disease-related genes) from the RIKEN mouse cDNA dataset using human curation plus FACTS, a new biological information extraction system
  270. A swollen abdomen: Part 1
  271. Systematic genome‐wide approach to positional candidate cloning for identification of novel human disease genes
  272. VIRAL ENCEPHALITIS IN HUMANS
  273. Use of Artificial Neural Networks in the Prediction of Kidney Transplant Outcomes
  274. FREP: a database of functional repeats in mouse cDNAs
  275. Autoimmune Diabetes in the NOD Mouse: An Essential Role of Fas‐FasL Signaling in β Cell Apoptosis
  276. Prevention of Autoimmune Diabetes through Immunostimulation with Q Fever Complement‐Fixing Antigen
  277. The Role of Endoplasmic Reticulum Stress in Nonimmune Diabetes: NOD.k iHEL, a Novel Model of β Cell Death
  278. Allergen databases
  279. Computational tools for the study of allergens
  280. Corrigendum
  281. Cytokine-Related Genes Identified From the RIKEN Full-Length Mouse cDNA Data Set
  282. Inferring Higher Functional Information for RIKEN Mouse Full-Length cDNA Clones With FACTS
  283. Identification of Novel “Pathologs” (Human Disease-Related Gene Candidates) From the RIKEN Full-Length Mouse cDNA Data Set
  284. Mechanisms of Accelerated Immune-Mediated Diabetes Resulting from Islet β Cell Expression of a Fas Ligand Transgene
  285. Bioinformatics for characterisation of allergens, allergenicity and allergic crossreactivity
  286. Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter‐regulator
  287. Vaccine Therapies for the Prevention of Type 1 Diabetes Mellitus
  288. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs
  289. Pregnancy‐associated osteoporosis with hypercalcaemia
  290. Evidence from twins for acquired cellular immune hyperactivity in type 1 diabetes
  291. Computational immunology: The coming of age
  292. Prediction of promiscuous peptides that bind HLA class I molecules
  293. Response of Serum Macrophage Migration Inhibitory Factor Levels to Stimulation or Suppression of the Hypothalamo-Pituitary-Adrenal Axis in Normal Subjects and Patients with Cushing's Disease
  294. The Role of Fas Ligand in Beta Cell Destruction in Autoimmune Diabetes of NOD Mice
  295. Methods for Prediction of Peptide Binding to MHC Molecules: A Comparative Study
  296. Severe diabetic retinopathy: a rare complication of acromegaly
  297. Prospects for the Prevention and Reversal of Type 1 Diabetes Mellitus
  298. Use of Artificial Neural Networks in Improving Renal Transplantation Outcomes
  299. Severe diabetic retinopathy: a rare complication of acromegaly
  300. Efficient discovery of immune response targets by cyclical refinement of QSAR models of peptide binding
  301. Towards a unified model of neuroendocrine–immune interaction
  302. Macrophage Migration Inhibitory Factor: A Critical Neurohumoral Mediator
  303. Molecular immunology databases and data repositories
  304. Macrophage Migration Inhibitory Factor (MIF): A Critical Neurohumoral Mediator
  305. DIURNAL RHYTHMS OF PRO-INFLAMMATORY CYTOKINES: REGULATION BY PLASMA CORTISOL AND THERAPEUTIC IMPLICATIONS
  306. The Chronobiology of Human Cytokine Production
  307. Danazol in the treatment of a systemic lupus erythematosus (SLE)‐like illness associated with deficiency of the fourth component of complement
  308. HLA Class II-associated polymorphism of interferon-γ production implications for HLA-disease association
  309. Evidence for the Viral Aetiology of IDDM
  310. A strategy for prediction of peptide binding affinity for the human peptide transporter
  311. The paradoxical association between immunodeficiency and autoimmunity: Comment on he article by Atkinson
  312. Th1 and Th2: swinging to a hormonal rhythm
  313. Cytokine-based human whole blood assay for the detection of antigen-reactive T cells
  314. T-cell receptor signal sequences
  315. HLA-matched control subjects are essential in studies of susceptibility to IDDM
  316. Difficulties and dangers of vaccination strategies for asthma and other autoimmune disorders
  317. Whole Blood Assays and the Influence of Circadian Rhythmicity on Human Cytokine Measurement
  318. Immunoinformatics—The New Kid in Town
  319. Use of Artificial Neural Networks in Improving Renal Transplantation Outcomes
  320. The Future for Computational Modelling and Prediction Systems in Clinical Immunology